RUNX family transcription factor 3Genealiases: AML2 · CBFA3 · PEBP2aC
Q-omics provides the consensus-scored RUNX3 profile across patient tissues and cancer cell-line models. RUNX3 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in LGG. Among the 18 cancer types available for tumor–normal comparison, RUNX3 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, RUNX3 protein abundance shows 17,536 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight LGG, KIRC, and LSCC as cancer lineages where RUNX3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RUNX3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RUNX3 survival associations across molecular data types. RUNX3 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (3) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RUNX3 RNA expression–survival associations across cancer types. High RUNX3 expression shows unfavorable associations in LGG, UVM and THYM, but favorable associations in LIHC, ESCA and HNSC. The LGG Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LGG as the clearest survival context for RUNX3 RNA expression.
This table summarizes RUNX3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for RUNX3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RUNX3 shows lower tumor expression in LUAD and higher tumor expression in KIRC, HNSC, KIRP, STAD and UCEC. The KIRC box plot shows higher RUNX3 RNA expression in tumor versus normal tissue (log2 FC = +2.593, t-test p < 0.001).
This table shows molecular features associated with RUNX3 in patient tissues and cancer cell lines. In patient samples, RUNX3 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, RUNX3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and SKIN.
